Princeton, NJ, September 01, 2006 --(PR.com
)-- New Life Scientific, Inc (NWLS) a developmental biotech company whose core focus is to develop and commercialize novel biotech/pharmaceutical products including vaccines and stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing, announced today that they have moved into their new corporate headquarters in Princeton, NJ.
Wieslaw Bochenek New Life’s President and CSO said: “it is an important event for our young company that brings us closer to the very active academic and biopharmaceutical community of the Princeton area. Close interaction with other scientists will be a motivating and inspiring factor for our staff.”
“The proximity of our headquarters to the major metropolitan areas of New York and Philadelphia with easy access to Washington DC will facilitate our contacts with the major financial and regulatory institutions” said Henry Val, New Life’s Chairman and CEO.
About New Life Scientific, Inc. (OTC BB:NWLS.OB - News): New Life Scientific, Inc. was formed with the intent to develop and commercialize novel biotech/pharmaceutical products including vaccines and stem cell based treatment modalities and to expand through our own research, collaborations, acquisitions and in-licensing. NWLS utilizes its strategic geographical positioning in Europe to seek undiscovered, emerging and under-valued biotechnologies in the countries of Eastern Europe, with the further intent of their commercialization. NWLS has two subsidiaries: PharmaTrials International (PTI), a provider of services in the areas of clinical trials, market research and the regulatory approval of products for pharmaceutical, biotech and medical device companies worldwide. Invamed Pharma, with expertise in development and commercialization of pharmaceutical/biotech products coming from its own pipeline of in-licensed and new therapeutic classes as well as reformulation of existing products using InvaPharm proprietary technology to improve therapeutic potential of drugs.
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.
For: New Life Scientific, Inc.